ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ensifentrine

Also written as “Ensifentrine”, “RPL554” and “Ensifentrine 3 mg”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Cystic Fibrosis · Asthma, led by 2 companies.

Drug pageEnsifentrine: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 19, 202017 company-led studies, 2 open or runningAcquisition: Merck acquired Verona Pharma, Oct 2025Next primary completion: Mar 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck152 open or runningphase 3since Aug 19, 2020Nov 30, 2014Mar 1, 2027phase 2 · NCT05270525
Nuance Pharma (shanghai)its history only20 open or runningphase 3since Feb 14, 2023Feb 14, 2023none ahead
  • Named in Merck’s own pipeline as ensifentrine (+) glycopyrrolate (MK-5884A), phase 2, as of Nov 2, 2026 (source).

Also a collaborator on its studies: Laboratory Corporation of America and Iqvia Pty.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

  • LicenseNuance Pharma licensed it from Verona Pharma, for Greater China (mainland China, Taiwan, Hong Kong and Macau).Agreed Jun 9, 2021 · Source: Verona Pharma (8-K), Jun 11, 2021
  • AcquisitionMerck acquired Verona Pharma, and with it ensifentrine (Ohtuvayre).Completed Oct 7, 2025 · Source: Merck, Oct 7, 2025

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 1 study since Nov 30, 2014.

  1. Apr 14, 2015Phase 2 study in AsthmaNCT02427165 · 29 enrolled · Sweden, United Kingdom
  2. Aug 30, 2015Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT02542254 · 36 enrolled · United Kingdom
  3. Sep 21, 2016Phase 2 study in Cystic FibrosisNCT02919995 · 10 enrolled · United Kingdom
  4. Jan 3, 2017Phase 2 study in Chronic Obstructive Pulmonary Disease ModerateNCT03028142 · 30 enrolled
  5. Feb 7, 2018Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT03443414 · 405 enrolled · Bulgaria, Czechia, Germany and more
  6. Jun 9, 2018Named ensifentrineINNProposed as its International Nonproprietary Name in WHO's List 119 · before, RPL554
  7. Sep 7, 2018Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT03673670 · 79 enrolled · United States, United Kingdom
  8. Jun 20, 2019Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT04091360 · 40 enrolled · United Kingdom
  9. Aug 19, 2020Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT04535986 · 763 enrolled · United States, Bulgaria, Czechia and more
  10. Sep 1, 2020Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT04542057 · 790 enrolled · United States, Belgium, Bulgaria and more
  11. Jun 9, 2021Nuance Pharma licensed it from Verona PharmaLicenseGreater China (mainland China, Taiwan, Hong Kong and Macau) · agreed · Verona Pharma (8-K)
  12. Feb 8, 2022Phase 2 study in Lung DiseasesNCT05270525 · 70 enrolled · United States
  13. Jun 10, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT06460493 · 20 enrolled · United States
  14. Jun 3, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07016412 · 497 enrolled · United States
  15. Aug 11, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07132983 · 33 enrolled · United States
  16. Oct 7, 2025Merck acquired Verona PharmaAcquisitionWith it ensifentrine (Ohtuvayre) · completed · Merck
  17. Sep 30, 2026Phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07874815 · 2,136 planned · United States

Ahead

  1. Mar 1, 2027Primary completion: phase 2 study in Lung DiseasesNCT05270525
  2. Apr 29, 2029Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveNCT07874815

TargetBeta

“An inhaled inhibitor of the phosphodiesterase (PDE) types 3 (PDE3) and 4 (PDE4), with potential anti-inflammatory and bronchodilator activities. Upon administration, ensifentrine targets, binds to and inhibits PDE3 and PDE4, which leads to an increase of both intracellular levels of cyclic-3',5'-…”NCIt, read by Claude
“An inhaled inhibitor of the phosphodiesterase (PDE) types 3 (PDE3) and 4 (PDE4), ”NCIt, by rule
“Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor”ChEMBL 37, by rule

Studies

All 15 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07874815Pulmonary Disease, Chronic Obstructive · United States3RecruitingApr 29, 20292,136
NCT07132983Pulmonary Disease, Chronic Obstructive · United States2CompletedNov 28, 202533
NCT07016412Pulmonary Disease, Chronic Obstructive · United States2CompletedAug 17, 2026497
NCT06460493Pulmonary Disease, Chronic Obstructive · United States3CompletedNov 26, 202420
NCT05270525Lung Diseases · United States2Active, not recruitingMar 1, 202770
NCT04542057Pulmonary Disease, Chronic Obstructive · United States, Belgium, Bulgaria and more3CompletedMay 3, 2022790
NCT04535986Pulmonary Disease, Chronic Obstructive · United States, Bulgaria, Czechia and more3CompletedSep 12, 2022763
NCT04091360Pulmonary Disease, Chronic Obstructive · United Kingdom2CompletedDec 10, 202040
NCT03673670Pulmonary Disease, Chronic Obstructive · United States, United Kingdom2CompletedNov 13, 201879
NCT03443414Pulmonary Disease, Chronic Obstructive · Bulgaria, Czechia, Germany and more2CompletedJan 23, 2018405
NCT03028142Chronic Obstructive Pulmonary Disease Moderate2CompletedAug 201730
NCT02919995Cystic Fibrosis · United Kingdom2CompletedNov 3, 201710
NCT02542254Pulmonary Disease, Chronic Obstructive · United Kingdom2CompletedDec 201536
NCT02427165Asthma · Sweden, United Kingdom2CompletedNov 201529
NCT02307162Pulmonary Disease, Chronic Obstructive · United Kingdom1CompletedJul 2015112

How it is read

Names in the registry

  • “Ensifentrine”, 7 entries
  • “RPL554”, 4 entries
  • “Ensifentrine 3 mg”, 2 entries
  • “Ensifentrine 1.5 mg”, 1 entry
  • “Ensifentrine 3 mg (marketed formulation)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.